You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 8,318,199

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,318,199

Title:	Liposome for liver-specific delivery and release of therapeutic nucleic acids or drugs
Abstract:	Disclosed herein is a composite of a nanoscale particle size. The composite is able to specifically deliver therapeutic agents such as therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects of the therapeutic agents. The composite may be comprised of an apolipoprotein A-1 and a liposome-forming material. A composition containing the composite and a pharmaceutically acceptable carrier is disclosed.
Inventor(s):	Kim; Meehyein (Yongin-si, KR), Kim; Soo In (Yongin-si, KR), Shin; Duckhyang (Yongin-si, KR), Park; Mahnhoon (Yongin-si, KR)
Assignee:	Mogam Biotechnology Research Institute (Yongin-si, KR)
Application Number:	12/791,600
Patent Claims:	1. A composition comprising: an isolated composite of an apolipoprotein A-1 and a liposome-forming material, said liposome-forming material being a mixture of 1,2-dioleoyl-3-trimethylammonium-propane and cholesterol, forming a liposome; a pharmaceutically acceptable carrier; and an isolated therapeutic agent which is targeted to be delivered to and released in the liver of a subject who is in need of receiving the therapeutic agent, encapsulated within the liposome. 2. The composition according to claim 1, wherein the therapeutic agent is a therapeutic nucleic acid. 3. The composition according to claim 2, wherein the therapeutic nucleic acid is an siRNA specific for HBV or HCV genome. 4. The composition according to claim 1, wherein the weight ratio of the apolipoprotein A-1 and the liposome-forming material is in the range of 1: 0.1 to 1: 1000. 5. The composition according to claim 1, wherein the therapeutic agent is an active polypeptide, an anticancer agent or an antivirus agent. 6. The composition according to claim 5, wherein the active polypeptide is selected from the group consisting of epidermal growth factor, erythropoietin, coagulation factors VIII, IX and VIIa, follicle stimulating hormone, granulocyte colony-stimulating factor, granulocyte-macrophage colony stimulating factor, insulin, insulin-like growth factor, interferon-.alpha., -.beta. and -.gamma., interleukin-1, -2, -11, -12 and -15, parathyroid hormone, platelet-derived growth factor, human growth hormone, tissue plasminogen activator, vascular endothelial growth factor, and a mixture thereof. 7. The composition according to claim 5, wherein the anticancer agent is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, heptaplatin, etoposide, semustine, hydroxycarbamide, citarabine, fludarabine, doxorubicin, epirubicin, idarubicin, pirarubicin, fluorouracil, fluoxuridine, mitomycin, bleomycin, clofazimine, interferon, streptozocin, gemcitabine, enocitabine, capecitabine, ursodeoxycholic acid, sorafenib, tegafur, holmium, a holmium-chitosan complex, and a mixture thereof. 8. The composition according to claim 5, wherein the antivirus agent is selected from the group consisting of atazanavir, ribavirin, zanamivir, acyclovir, entecavir, didanosin, nevirapine, valaciclovir, nelfinavir, efavirenz, ganciclovir, lamivudine, famciclovir, stavudine, abacavir, indinavir, oseltamivir, inosiplex, adefovir, and a mixture thereof.

Details for Patent 8,318,199

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004	⤷ Try a Trial	2026-11-09
Schering Corporation A Subsidiary Of Merck & Co., Inc.	PEGINTRON/ REBETOL COMBO PACK	peginterferon alfa-2b and ribavirin		125196	06/13/2008	⤷ Try a Trial	2026-11-09
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015	⤷ Try a Trial	2026-11-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.